Indication

21-Hydroxylase Deficiency

1 clinical trial

1 product

Clinical trial

A Phase 2 Study to Evaluate the Safety, Efficacy and Pharmacokinetics of SPR001 (Tildacerfont) in Children Aged 2 to 17 Years With Congenital Adrenal Hyperplasia

Status: Recruiting, Estimated PCD: 2024-12-01

Product